Zhang et al. reported that activating AXL caused resistance to EGFR-targeted TKIs such as erlotinib in lung cancer, and that genetic and pharmacological inhibition of AXL restored TKI sensitivity16. The gene discussed is EGFR; the disease is lung carcinoma.